The downgrade from Overweight to Equal-Weight by Wells Fargo suggests a less bullish outlook on Zymeworks, which could lead to a negative short-term impact on the stock price. The maintained price target indicates no expected change in valuation, but the downgrade itself may influence investor sentiment.